Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
4.060
-0.350 (-7.94%)
At close: Oct 31, 2024, 4:00 PM
4.170
+0.110 (2.71%)
After-hours: Oct 31, 2024, 4:16 PM EDT

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
4.262.370.020.01
Research & Development
1.871.570.830.13
Operating Expenses
6.123.940.850.14
Operating Income
-5.42-3.94-0.85-0.14
Interest Expense
-5.86-1.64--
EBT Excluding Unusual Items
-11.26-5.59-0.85-0.14
Other Unusual Items
-7.49-7.49--
Pretax Income
-18.74-13.07-0.85-0.14
Net Income
-18.74-13.07-0.85-0.14
Net Income to Common
-18.74-13.07-0.85-0.14
Shares Outstanding (Basic)
292727-
Shares Outstanding (Diluted)
292727-
Shares Change (YoY)
5.23%1.77%--
EPS (Basic)
-0.66-0.48-0.03-
EPS (Diluted)
-0.66-0.48-0.03-
Free Cash Flow
-6.55-3.86-0.47-0.12
Free Cash Flow Per Share
-0.23-0.14-0.02-
EBIT
-5.42-3.94-0.85-0.14
Source: S&P Capital IQ. Standard template. Financial Sources.